1. 1194 Biomonitoring of health care personnel involved in the preparation and administration of anticancer drugs in three italian hospitals. (24th April 2018) Authors: Ursini, CL; Cavallo, D; Omodeo Salè, E; Fresegna, AM; Ciervo, A; Jemos, C; Maiello, R; Buresti, G; Colosio, C; Rubino, FM; Delrio, P; Maiolino, P; Marchetti, P; Boccia, R; Iavicoli, S Journal: Occupational and environmental medicine Issue: Volume 75(2018)Supplement 2 Page Start: A320 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1736PClinical impact of whey protein and nutritional counseling in gastrointestinal cancer patients. (23rd October 2018) Authors: Roberto, M; Sarfati, E; Di Girolamo, M; Schipilliti, F M; Crimini, E; Botticelli, A; Marchetti, L; Muscaritoli, M; Marchetti, P; Mazzuca, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 53PImmune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme. (17th December 2018) Authors: Baldini, E; Lunghi, A; Cortesi, E; Turci, D; Garassino, M C; Stati, V; Ardizzoni, A; Ricciuti, B; Frassoldati, A; Romano, G; Illiano, A; Verderame, F; Fasola, G; Marchetti, P; Pinto, C; Carteni, G; Scotti, V; Tibaldi, C; Fioretto, L; Giannarelli, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 55P Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study. (15th December 2019) Authors: Nigro, O; Cortellini, A; Giusti, R; Marchetti, P; De Galitiis, F; Di Pietro, F R; Bersanelli, M; Lazzarin, A; Galetta, D; Pizzutillo, P; Santini, D; Torniai, M; De Giglio, A; Russo, A; Silva, R R; Bolzacchini, E; Natoli, C; Rijavec, E; Vallini, I; Pinotti, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 583PThromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial. (23rd October 2018) Authors: Barni, S; Rosati, G; Zagonel, V; Pella, N; Banzi, M; Zampino, M G; Di Bartolomeo, M; Rimassa, L; Marchetti, P; Maiello, E; Artioli, F; Ferrari, D; Labianca, R; Bidoli, P; Zaniboni, A; Sobrero, A; Iaffaioli, V; de Placido, S; Frassineti, L G; Galli, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. CPC-012 An Italian Cost-Effectiveness Analysis of Paclitaxel Albumin (Nab-Paclitaxel) Vs. Conventional Paclitaxel For Metastatic Breast Cancer Patients: The COSTANZA Study. (12th March 2013) Authors: Lazzaro, C; Bordonaro, R; Cognetti, F; Fabi, A; De Placido, S; Arpino, G; Marchetti, P; Botticelli, A; Pronzato, P; Martelli, E Journal: European journal of hospital pharmacy Issue: Volume 20(2013)Supplement 1 Page Start: A169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P-101A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy. (2nd July 2019) Authors: Parisi, A; Cortellini, A; Roberto, M; Venditti, O; Santini, D; Dell'Aquila, E; Stellato, M; Marchetti, P; Occhipinti, M; Zoratto, F; Mazzuca, F; Tinari, N; De Tursi, M; Iezzi, L; Natoli, C; Ratti, M; Pizzo, C; Ghidini, M; Ficorella, C; Cannita, K Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P-160Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours. (2nd July 2019) Authors: Roberto, M; Arrivi, G; Milano, A; D'Antonio, C; Romiti, A; Falcone, R; Mazzuca, F; Fais, S; Marchetti, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P-206Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers. (20th June 2018) Authors: Bruera, G; Massacese, S; Pepe, F; Malapelle, U; Dal Mas, A; Ciacco, E; Calvisi, G; Marchetti, P; Troncone, G; Simmaco, M; Ricevuto, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P-206Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers. (20th June 2018) Authors: Bruera, G; Massacese, S; Pepe, F; Malapelle, U; Dal Mas, A; Ciacco, E; Calvisi, G; Marchetti, P; Troncone, G; Simmaco, M; Ricevuto, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗